U.S. Markets closed

InnovAge Holding Corp. (INNV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.00-0.75 (-3.16%)
At close: 4:00PM EDT

23.19 +0.19 (0.83%)
After hours: 4:02PM EDT

Sign in to post a message.
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is down 6.09% to 21.60
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is down 5.38% to 24.10
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is down 7.10% to 23.96
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is up 7.16% to 25.74
  • s
    stocktargetadvisor
    $INNV
    Initiates Coverage On William Blair Outperform
    Initiated by Goldman Sachs Buy USD 32
    Initiated by Citigroup Buy USD 30
    Initiates Coverage On Piper Sandler Overweight USD 31
  • M
    Marie2Dessy
    Are these posts from another stock?
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is down 6.87% to 24.01
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is up 10.35% to 26.76
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is down 5.58% to 24.53
  • Y
    Yahoo Finance Insights
    Innovus Pharmaceuticals is up 4.97% to 24.30
  • K
    KM
    Innovus Pharmaceuticals, Inc.
    Innovus Pharma inks deal with Pharma Solutions for Zestra, Zestra Glide, Ejectdelay and Sensum+ https://seekingalpha.com/news/3315644?source=ansh $INNV
    Innovus Pharmaceuticals (OTCQB:INNV) announces the signing of an exclusive license and distribution agreement with Corporacion Pharma Solutions Peru SAC, a Peruvian company for the commercialization
    Innovus Pharmaceuticals (OTCQB:INNV) announces the signing of an exclusive license and distribution agreement with Corporacion Pharma Solutions Peru SAC, a Peruvian company for the commercialization
    seekingalpha.com
  • J
    Joe Seff
    $INNV conversation
    Hey, alot of us longs are feeling pretty good today...it's Easter and an important development has finally happened after YEARS of waiting ! Perhaps buy some INNV product today and send out a couple of posts/tweets to those in need on popular HealthCare message boards, sites, and forums. Tout product to help others while you help yourself. It's Free marketing, takes a couple of minutes, and reaches the proper target audiences so sales are more likely to happen. WHY not do it ?

    * Enjoy your Easter brunches !!

    #INNV
  • C
    CooterMcGavinn
    Innovus Pharmaceuticals, Inc. (INNV) CEO Bassam Damaj on Q3 2018 Results - Earnings Call Transcript $INNV https://seekingalpha.com/article/4222329
    Innovus Pharmaceuticals, Inc. (OTCQB:INNV) Q3 2018 Results Earnings Conference Call November 14, 2018, 04:15 PM ET Executives Bassam Damaj - President and CEO R
    Innovus Pharmaceuticals, Inc. (OTCQB:INNV) Q3 2018 Results Earnings Conference Call November 14, 2018, 04:15 PM ET Executives Bassam Damaj - President and CEO R
    seekingalpha.com
  • H
    HK Lewis
    Innovus Pharmaceuticals, Inc.
    There is no bad news out but the stock price is only going down because of no good news. The fact is that the FDA has been slow on about all ANDA approvals recently not just Fluticare. Also, the stock is undervalued without Fluticare. They are expecting to be profitable without Fluticare. The CEO is heavily invested at 40 cents.
  • M
    Matthew
    Fellow INNV longs: let's agree to not sell any significant number of shares to maximize the pain and accelerate the shirt squeeze.
  • S
    Syd
    $INNV conversation
    I can't understand why some people are already frustrated with Innovus on just the third day of trading for the new year.
    Nothing has changed from last week, or two weeks ago or for that matter, two months ago. The company is still waiting for the FDA approval for its ANDA which we all know can take up to 36 months. Granted we are impatient but no bad news has been released. There is no dilution of shares. Innovus has not increased the shares outstanding since the approval and intends to do so only with specific purposes which will accelerate growth. The vote merely gave the CEO the flexibility to do so if an appropriate opportunity arises. Also (and I posted this before) the CEO purchased his $2.5 million worth of shares (6.25 million shares) at a 0.40 cent cost basis and I am positive is very cognizant of appropriate uses for any additional shares. I know that people on this board have expressed concerns about dilution but let's not create panic. Granted dilution without increasing shareholder value is always a negative. But if dilution increases future earnings and revenue at a rate faster than increased share count, then that is positive or accretive. Almost all mid-sized and large companies have utilized accretive dilution as an appropriate way to deliver increased shareholder value and have done so at many points in their history. So why all the fuss? Nothing has changed.
    I have realistic expectations of Innovus as the new year starts. I am not going to panic when this stock moves down or up by 2 or 3 or 5 cents. The malicious market-makers are trying to short INNV but are not having much luck.
    None of the nine (9) institutional investors is trying to sell and they have over 12 million shares.
    These nine investors gave INNV $3 million in exchange for 12 million shares (priced at 0.25) and almost all that debt has now been converted before the maturity date so there is no issue there. While I am not able to speculate on what these investors will do in the future, I can hypothesize that they want INNV to go as high as it has the potential to go.
    By the way, I am not making this stuff up. Please feel free to review a previous S1 (filed with the SEC 8/9/16), Pg-3.

    Team my plan is to listen to the Q4 2016 earnings call (in mid-Feb), patiently wait for the FDA approval, get positive guidance for 2017 and gradually see the SP go up later this year. I own a lot of shares (more than I should own) but I truly believe in this company and its mid to long-term success possibilities. This company will not evaporate as some may have suggested. I am not going to get frustrated every day when this stock bounces-around because the fundamentals for INNV are in good shape despite the MM trying their best to manipulate/derail it. Hang-in there longs; our day is coming.
  • S
    Syd
    $INNV conversation
    Team - I went back and analyzed last week's statements by the CEO and those by the Lertal management, and it appears that Innovus is now also focusing on PEDIATRIC indications for allergies as Lertal was conducting multi-center placebo trials for its pediatric patients. I think instead of us focusing on "eventual FDA approval of FlutiCare" line, we should focus on how Dr. Damaj is trying to pair his OTC generic nasal spray FlutiCare with Lertal and gain a competitive advantage over Flonase and ClariSpray et cetera. Dr. BD is a very smart guy and has always thought outside the proverbial box. And in many ways he has to do that because he is up against heavyweights GlaxoSmithKline and Bayer....kind of like David against Goliath. Any way, team the naysayers and the malicious NITE's of the world have tried to bring Innovus down but have not succeeded; not really, and so the story continues into 2017. I am now more confident than ever that this tiny, nano cap company will eventually (in 12 to 18 months) break-through and attain its fair place in the bigger market. Dr. Damaj paid $5 million for Novalere rights to sell FlutiCare and then put $2.5 million of his own money (with a 0.40 cent cost basis) to show us he is fully vested and confident in the company's financial performance. Dr. Damaj has never shown that he is reckless or thoughtless. Quite to the contrary, he is astute, experienced and is laying the foundation for building his company. He will get FDA approval, capture 5% to 8% of the $1 billion allergy rhinitis market, continue to focus on recession-proof products, continue his behind the scene efforts to one day up-list when the timing is right so I am not worried. To all those who have been negative about Innovus, I have no ill-will and nothing harmful to say. I will let the stock symbol INNV:OTC do the talking in 2017.

    Here are excerpts from the press-release a couple of days ago:
    “Strengthening our respiratory franchise is an important goal for us and adding more products such as Lertal® as a cross sell or potentially in a kit format with FlutiCare™, when that product is eventually approved by the FDA, will give Innovus Pharma an immense advantage over our competitors,” said Innovus Pharma Chief Executive Officer Dr. Bassam Damaj. “We continue to look at other respiratory products to in-license to further build out our respiratory franchise.”

    “We are proud to be partnering with Innovus Pharma in the US and Canada so Lertal® will be available to patients who regularly suffer from allergy symptoms,” said Dr. Riccardo Carbucicchio, Chief Executive Officer of NTC. “Innovus Pharma was positively impressed with our promising clinical trial results of Lertal® which saw reductions in both nasal and ocular symptoms in allergic patients. In view of these results, we are now supporting another larger randomized, multicenter, placebo controlled study in perennial and seasonal allergy in pediatric patients. Lertal® is meant to contribute to a reduction in daily consumption of anti-allergic drugs.”
  • T
    Truthbetold
    $INNV conversation
    I have a new theory as to this self-imposed quiet period...1. they hired a legit CFO, 2) they issued remaining shares to Novalere, 3) they authorized millions of shares for "future use", 4) No mention of additional signings, deals etc...my conclusion...drum role please...they are in partnership/buyout talks with another company. The partnership/buyout will be announced within days (not weeks) after ANDA approval...
  • J
    John
    $INNV conversation
    As many investors wait for FDA the stock is ruling out the impatient ones. Mind you this stock is becoming extremely undervalued especially given the product pipeline they have and future business. It might seem to be heading south now but gains will be here soon
  • M
    Matthew
    One of these days -- sooner than later--we will wake up to an FDA announcement on Fluticare. For investors it will be a dream come true; for (naked) shorts, they will wake up to a nightmare. I'm thinking end of Sept to end of Oct.